Compare ADPT & COCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | COCO |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2019 | 2021 |
| Metric | ADPT | COCO |
|---|---|---|
| Price | $21.28 | $66.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $17.78 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | 26.60 |
| EPS | N/A | ★ 0.50 |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | $16.12 |
| Revenue Next Year | $22.72 | $11.40 |
| P/E Ratio | ★ N/A | $132.32 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $9.96 | $31.82 |
| 52 Week High | $22.80 | $85.83 |
| Indicator | ADPT | COCO |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 33.26 |
| Support Level | $15.08 | $48.98 |
| Resistance Level | N/A | $69.59 |
| Average True Range (ATR) | 1.27 | 4.19 |
| MACD | 0.33 | -2.28 |
| Stochastic Oscillator | 76.67 | 2.72 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.